Latest News
AstraZeneca completes global licence agreement for Zegfrovy
1 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Tuesday it has completed its exclusive global licence agreement with China-based Dizal Pharmaceutical Co., Ltd (SSE: 688192) for Zegfrovy (sunvozerti...
AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer
1 September 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) on Tuesday announced European Commission approval for Enhertu (trastuzumab de...
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
1 September 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for neurodegenerative diseases, announced on Monday a redesigned development plan for PrimeC in amyotrophic lateral ...
Prasco increases Ohio pharmaceutical footprint
1 September 2026 - Prasco LLC, a pharmaceutical commercialisation company specialising in authorised generics, today announced on Monday the acquisition of a strategically located distribution facility in Carey, Ohio.Prasco said that the 130,000+ squ...
UCB agrees with US government to lower medicine costs and strengthen US manufacturing
1 September 2026 - Belgium-based biopharmaceutical company UCB (EBR:UCB) announced on Monday that it has reached an an agreement with the US government that will continue to support patient access to important medicines while enabling significant inv...